clinical trial · NCT07454720
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II/III Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Rectal Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.·phase3·not yet recruiting·n = 165
Locally Advanced Resectable Rectal CancerAdebrelimab in combination with SHR-8068 and chemotherapyAdebrelimab combined with chemotherapychemotherapy
brief summary
The study is being conducted to evaluate the safety and efficacy of Adebrelimab and SHR-8068 in combination with chemoradiotherapy in subjects with rectal cancer
started
Mar 1, 2026
primary completion
Nov 1, 2032
completion
Nov 1, 2035
last updated
Mar 6, 2026
official title
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II/III Clinical Study of Adebrelimab Combined With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Resectable Rectal Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol